Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The objective of the trial is to investigate the effect of different degrees of renal
impairment on the pharmacokinetics and safety of the combination of BI 207127 and faldaprevir
after 3 days of dosing (BI 207127 bid, faldaprevir qd) and a single dose of BI 207127 and
faldaprevir on day 4.